ImmunityBio Securities Class Action Lawsuit
Analysis based on 6 articles · First reported Apr 02, 2026 · Last updated Apr 21, 2026
The market is impacted by the potential financial liabilities for ImmunityBio due to the securities class action lawsuit, which could lead to a further decline in its stock price. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, may suffer damages.
Faruqi & Faruqi, LLP has filed a federal securities class action lawsuit against ImmunityBio, Inc. and its executives, including Patrick Soon-Shiong. The complaint alleges that Patrick Soon-Shiong materially overstated Nogapendekin alfa inbakicept's capabilities, leading to false and misleading statements about ImmunityBio's business, operations, and prospects. This alleged misconduct resulted in investors suffering damages, particularly after ImmunityBio's stock price fell by 12.13% on January 23, 2026, following a press release about its QUILT 3.078 clinical trial results. The deadline for investors to seek the role of lead plaintiff is May 26, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard